Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness

Micro-Abstract Colorectal cancer (CRC) screening with a multitarget stool DNA test was recently approved by the Food and Drug Administration. We used clinical effectiveness modeling to compare test intervals of 1, 3, or 5 years on CRC incidence and related mortality to help inform screening guidelin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2016-09, Vol.15 (3), p.e65-e74
Main Authors: Berger, Barry M, Schroy, Paul C, Dinh, Tuan A
Format: Article
Language:English
Subjects:
Archimedes
Colonoscopy
Colorectal Neoplasms - diagnosis
Cost-Benefit Analysis
DNA - analysis
Early Detection of Cancer - economics
Early Detection of Cancer - methods
Feces - chemistry
Gastroenterology and Hepatology
Guidelines
Hematology, Oncology and Palliative Medicine
Humans
Mass Screening - economics
Mass Screening - methods
Models, Biological
Models, Theoretical
Utility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Colorectal cancer (CRC) screening with a multitarget stool DNA test was recently approved by the Food and Drug Administration. We used clinical effectiveness modeling to compare test intervals of 1, 3, or 5 years on CRC incidence and related mortality to help inform screening guidelines. Our results showed that screening every 3 years provides reasonable performance at acceptable cost.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2015.12.003